Your browser doesn't support javascript.
Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from PREPARE-IBD
Lamb, Christopher, Shaji, Sebastian, Kent, Alexandra J.; Segal, Jonathan P.; Gonzalez, Haidee A.; Brookes, Matthew J.; Mehta, Shameer J.; Subramanian, Sreedhar, Bhala, Neeraj, Hicks, Lucy C.; Conley, Thomas E.; Patel, Kamal V.; Walker, Gareth J.; Kennedy, Nicholas A..
Gut ; 70(Suppl 4):A23, 2021.
Article in English | ProQuest Central | ID: covidwho-1506274
ABSTRACT
ATU-3 Frigure 1ConclusionsOur data provide reassurance for the continued evidence-based use of corticosteroids, immunomodulators and biologic therapies in IBD during the ongoing COVID-19 pandemic, and is consistent with an as yet unexplained association between mesalazine use and severe COVID-19 outcomes.
Fulltext
Print
XML
Search on Google

Full text: Available Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Language: English Journal: Gut Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
Search on Google

Full text: Available Collection: Databases of international organizations Database: ProQuest Central Type of study: Prognostic study Language: English Journal: Gut Year: 2021 Document Type: Article